Cancer Gene Therapy (Immunotherapy)

IL-2 Transduced Tumor Cells Effective Against Pancreatic Cancer

Published in Cancer Weekly, April 14th, 1997

Specific active immunotherapy using interleukin-2 (IL-2) gene-transduced tumor cells inhibits established pancreatic cancer in a murine model.

Although scientific advances have been made in several cancer treatment areas, the survival of patients with pancreatic cancer of exocrine origin has changed relatively little in the past 30 years. Unfortunately, 90 percent of pancreatic cancer patients are diagnosed as unresectable with metastases to regional lymph nodes, the liver and peritoneal surfaces. Even in patients who are surgically resectable, median survival does not exceed two years, and the five year survival rate is a dismal 15-25 percent. New and innovative...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry